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The solutions to emerging disease problems
involve politics and policy issues, as well as solid
science. The National Academy of Sciences’
Institute of Medicine (IOM), whose mission is to
“improve the health of people of the nation and
the world,” draws upon the expertise of elected
members as well as others in the United States
and other nations to make policy recommenda-
tions. Groups convene to debate contentious
issues and publish evidence-based reports with
recommendations to government, academia,
industry, and the public.
Evidence-based reports are the foundation
upon which policy can be built. In this last decade,
IOM has produced several documents that have
focused on emerging infections and provided a
springboard for policy on a local, nationwide, and
international scale. The U.S. Capacity to Address
Tropical Infectious Disease Problems (1987) (1)
concluded that U.S. capacity was barely adequate
and that improvement in policies and modest
additional funding could make a substantially
stronger contribution to the field. Required
efforts included sustained support for basic and
applied research; accelerated development and
testing of new preventive, therapeutic, and
diagnostic technologies; sustainable career struc-
tures for tropical disease professionals; increased
capacity to train U.S. tropical disease profession-
als and those from developing countries in research
and public health service; development of disease
surveillance capabilities; strengthened institu-
tional capabilities in developing countries; and
flexible, responsive administration of programs.
The Future of Public Health (1988) (2)  report
made three basic recommendations regarding
the mission of public health and defined its core
functions to be assessment, policy development,
and assurance. It also included guidance for the
government’s role in fulfilling the public health
mission and the responsibilities unique to each
level of government. The report has been a useful
blueprint for the past decade.
Emerging Infections: Microbial Threats to
Health in the United States (1992)(3) identified
significant emerging infectious diseases, deter-
mined what might be done to deal with them, and
recommended how similar future threats might
be confronted to lessen their impact on public
health. The document focused on factors
contributing to disease emergence, not the
diseases themselves: human demographics and
behavior, technology and industry, economic
development and land use, international travel
and commerce, microbial adaptation and change,
and the breakdown of public health measures.
Sexually Transmitted Diseases: The Hidden
Epidemic (1997) (4) focused on the need for a new
social norm of healthy sexual behavior. The small
investment in prevention efforts was contrasted
with the very high costs of care for treating
sexually transmitted diseases (STDs) (Figure 1).
The report also examined the obstacles and
opportunities presented by managed care.
Limitations include the low priority for STD
prevention, emphasis on short-term cost savings,
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Figure 1. Estimated annual direct and indirect costs
for selected sexually transmitted diseases (STDs) and
their complications in 1994 versus national public
investment in STD prevention and research in federal
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varying technical capabilities for diagnosis and
treatment, and patient concerns about confiden-
tiality and treatment of partners not enrolled in
the same health plan. Lastly, opportunities for
training and continuing education in STD control
and prevention are not built into most managed
care settings. The report called for several steps
including a national campaign to heighten
awareness of the human and financial costs of
STDs and to promote the use of social marketing
techniques for their prevention. A recent
innovative informational campaign used a niche
approach and a social marketing strategy with
the spot video Hittin’ the Skins and the public
service announcement Knockin’ Boots (D.
Futterman, pers. comm.), geared toward
alerting 16- to 21-year-olds of the need for HIV
testing.
Many related activities, in addition to the
IOM reports, have underscored the danger of
emerging infectious diseases and reiterated the
warnings about the overall erosion of the U.S.
public health system during the 1990s. The
reports also provided specific, detailed recom-
mendations for action by individual agencies. In
1994, the Centers for Disease Control and
Prevention (CDC) published Addressing Emerg-
ing Infectious Disease Threats: A Prevention
Strategy for the United States. In the same year,
the U.S. National Science and Technology
Council’s Committee on International Science,
Engineering, and Technology (an interagency
working group) was convened to consider the
global threat of emerging and reemerging
infectious diseases and in 1995 published the
report Infectious Disease—A Global Health
Threat. In 1995, the National Security Council
asked the federal government to examine its
preparedness to respond to global epidemics.
In 1995, the Food Safety and Inspection
Service, CDC, and the Food and Drug
Administration (FDA) developed the Sentinel
Site Study, which evolved into FoodNet and
now includes collection of more precise
information on the incidence of foodborne
disease in the United States. In 1996, President
Clinton’s administration set out a new policy to
establish a worldwide infectious disease
surveillance and response system and expand
certain federal agency mandates to better
protect American citizens.
In the 1996 NIAID Research Agenda for
Emerging Infectious Diseases, the National
Institutes of Health described research and
training issues relevant to the national strategy
for confronting the threat of emerging and
reemerging infections and related its approach to
addressing these issues.
In 1996, the Department of State established
an Emerging Infectious Diseases and HIV/AIDS
Program to serve as a focal point for the
development and implementation of U.S. foreign
policy objectives to improve the health of U.S.
citizens and to stem the spread of infectious
diseases worldwide through various interna-
tional bilateral and multilateral negotiations.
This program has received $50 million in
funding. Other government agencies, including
FDA, U.S. Agency for International Develop-
ment, Department of Defense, National Oceanic
and Atmospheric Administration, National Aero-
nautics and Space Administration, and U.S.
Department of Agriculture, have also examined
the issue of U.S. vulnerability to epidemics and
resurgence of infectious disease threats.
The IOM’s Forum on Emerging Infections is
the most recent activity within the National
Academy of Sciences to keep sustained attention
on these issues. The forum was established in
1996 to provide a structured opportunity for
discussion and to scrutinize critical, and possibly
contentious, scientific and policy issues related to
research on and the prevention, detection, and
management of new and reemerging infections.
The forum has organized a series of workshops to
be conducted over 30 months. Workshop topics
include costs of infectious diseases, surveillance,
antimicrobial resistance, effects of health-care
restructuring on public health and basic research
related to infectious diseases, capacity for
emergency response to emerging and reemerging
infectious diseases, education and training needs,
predicting the future, and behavioral interventions.
Orphans and Incentives (5), a 1998 report, is
the first publication of the forum; it focused on
constraints that have left an undefined group of
“urgently needed medical products in an
orphaned condition which demands special
attention.” The authors examined these products
across the product cycle and then classified them
into categories for which incentives might be
developed to bolster the competitiveness of such
products in industrial portfolios.
The 1998 report Antimicrobial Resistance (6),
the second publication of the forum, examined
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resistant strains, compromised persons (includ-
ing HIV-infected patients), deaths from infection
with resistant organisms, speed of the global
spread, and costs of health care. The report also
examined decreases in the antimicrobial arma-
mentarium, amount of research and develop-
ment expended when resistance was not seen as a
major threat, and funding for public health
infrastructure and addressed the following
topics: expansion, coordination, and improve-
ment of the diverse elements of surveillance;
need for relatively small but thoughtful
investments in research, clinical management
and practice, and policy; use of antibiotics in food
production; ways to prolong the effectiveness of
existing antibiotics; basic research and incentives
for new antibiotics; and legal and regulatory
mechanisms in key areas of need.
A soon-to-be-published report on a March
1998 workshop on managed care will examine the
implications of managed care systems on
emerging infections by reviewing basic and
clinical research, clinical practice guidelines,
surveillance and monitoring, prevention, educa-
tion and outreach, and product development.
These reports and events have examined
research on emerging infectious diseases and
crafted a series of policy recommendations.  They
put forth a rationale for why the United States
should invest in global health. The 1997 report,
entitled America’s Vital Interest in Global Health
(7), provided a new framework for thinking about
the benefits to the United States, as well as to the
rest of the world, of our increased participation.
The movement of two million people each day
across national borders and the growth of
international commerce are inevitably associated
with transfers of health risks (e.g., infectious
diseases, contaminated food, terrorism, and legal
or banned toxic substances). U.S. commitment to
global health serves to protect our people, enhance
our economy, and advance our international
interests. Moreover, governments are no longer the
sole agents in the global health arena (Figure 2).
The United States can contribute not only
with funding, but also with the scientific and
technical expertise in its health sector. The
United States should lead from its strengths
(medical science and technology) in the areas of
research and development, surveillance, educa-
tion and training, global partnerships, and
coordination and leadership. In this way, the
United States “can do well by doing good.”
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Figure 2. The growing role of the World Bank in
health (7).